BioSpace News Archive

WW International, Inc. (Nasdaq: WW), a global wellness company powered by the world’s leading commercial weight management program, today announced that it will present at the following virtual investor conference. KeyBanc Capital Markets’ Future of Technology Series Tuesday, September 8, 2020 at 11:20 a.m. ET Presenters: Mindy Grossman, President and Chief Executive Officer, and Nick Hotchkin, Chief Financial Officer, Operating Officer, North A

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced completion of the 1,000th surgery utilizing its Pediatric Nailing Platform | FEMUR, the first system specifically designed and developed to address the unique pediatric anatomies when treating femoral fractures and deformity correction procedures.

North American Partners in Anesthesia (NAPA) is the top-ranked Anesthesia Management Services outsourcing vendor in the 2020 Black Book Survey, maintaining its first-place position for the fourth consecutive year. NAPA is one of the leading single-specialty anesthesia and perioperative management companies in the U.S. Founded in 1986, we now provide services to more than 500 facilities in more than 20 states. The annual survey is conduct

- Topline results targeted for Q2 2021, less than a year away - - SB206, if approved, has the potential to meet an important need for the treatment of molluscum, an area with no current FDA-approved treatment - MORRISVILLE, N.C., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the first patient has been enrolled and dosed in its B-SIMPLE4 pivotal Phase 3 clinical study of SB206, a topical antiviral gel, for the treatment of

Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, today announced the publication of the results from its initial study evaluating the RheOx ™ Bronchial Rheoplasty System for chronic bronchitis. The 12-month data published in the American Journal of Respiratory and Critical Care

Antios Therapeutics, Inc. (“Antios”), a biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases, today announced a digitally available oral presentation at the European Association for the Study of the Liver (EASL) Digital International Liver Congress™ 2020. The title of the abstr

Boundless Bio , a company developing innovative new therapies directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today announced it will present a corporate overview at Citi’s 15th Annual BioPharma Virtual Conference. Date: Tuesday, September 8th Time: 4:40 p.m. EDT Presenter: Zachary Hornby, President and Chief Executive Officer of Boundless Bio About Boundless Bio Boundless Bio is a

LLS partners with PRA to help manage industry-first LLS PedAL master clinical trial to address the urgent need for new treatments for pediatric acute leukemia [03-September-2020] RYE BROOK, N.Y. and RALEIGH, N.C. , Sept. 3, 2020 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and PRA Health Sciences (NASDAQ: PRAH) announced today a partnership to launch a

Business Activity Index at 62.4%; New Orders Index at 56.8%; Employment Index at 47.9%; Supplier Deliveries Index at 60.5%

Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Brigham and Women’s Faulkner Hospital is the first provider in Massachusetts to offer the Sonata® System as a treatment for symptomatic u